Privia Health (PRVA) Research & Development (2020 - 2026)

Privia Health's Research & Development history runs 7 years deep, the most recent figure standing at $8.1 million for Q1 2026.

• On a quarterly basis, Research & Development rose 17.51% year-over-year to $8.1 million in Q1 2026; TTM through Mar 2026 was $28.3 million, a 3.9% increase from a year earlier, with the FY2025 full-year figure at $27.1 million, up 2.61% from the prior year.
• Research & Development rose to $8.1 million in Q1 2026 per PRVA's latest filing, from $6.4 million in the prior quarter.
• Across five years, Research & Development topped out at $8.1 million in Q1 2026 and bottomed at $4.7 million in Q1 2022.
• The 5-year median for Research & Development is $6.4 million (2025), against an average of $6.2 million.
• Biggest YoY gain for Research & Development was 46.39% in 2022; the steepest drop was 56.89% in 2022.
• Year by year, Research & Development stood at $5.2 million in 2022, then gained by 20.8% to $6.2 million in 2023, then increased by 3.41% to $6.5 million in 2024, then fell by 0.2% to $6.4 million in 2025, then grew by 26.13% to $8.1 million in 2026.
• Per Business Quant, the three latest PRVA Research & Development figures stand at $8.1 million (Q1 2026), $6.4 million (Q4 2025), and $7.0 million (Q3 2025).